CUTTING EDGE of TRANSPLANTATION

TRANSPLANT SUMMIT 2018

Breaking Through Regulatory Barriers to Unleash Transplant Innovation

FEBRUARY 8–10, 2018
Arizona Biltmore
Phoenix, AZ

For more information, visit www.myAST.org/meetings
How can Veloxis Transplant Support help my patients?

Veloxis Transplant Support can help provide access to medications for your patients, regardless of their circumstances. Available support includes a free 30-day starter pack, $0 Co-pay*, and Patient Assistance Program**.

Wow! My patients can definitely benefit from a co-pay card. How can I receive assistance?

Simply by calling Veloxis Transplant Support at 1-844-VELOXIS or by speaking with your local Veloxis Transplant Account Manager.

Eligibility Requirements

* Eligible insured patients can save up to a maximum benefit of $5,000 annually off the patient’s co-pay or out-of-pocket expenses of ENVARSUS XR. Patient is responsible for any differential over $5,000. This offer can be used an unlimited number of times. Offer not valid for cash-paying patients or where drug is not covered by the primary insurance. This offer is valid in the United States. No substitutions permitted. Offer not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefit plan, Tricare, or other federal or state health programs (such as medical assistance programs).

** Patient Eligibility for Free Trial Offer: This voucher is good for patients according to the following eligibility criteria and Terms of Use below. No claim for reimbursement for product dispensed pursuant to this voucher may be submitted to ANY third-party payer, whether a commercial, private, or a government payer. This offer is not insurance and is not valid for mail order. Quantity limits may apply. Terms of Use: This voucher may be redeemed with an accompanying prescription for a 30-day free trial of a Veloxis medication. No substitutions permitted. This voucher is good for the purchase of a Veloxis medication and lawfully purchased from an authorized retailer or distributor in the United States. Offer not valid where prohibited by law, taxed, or restricted. Offer is not transferable, is limited to one per person, and may not be combined with any other offer. Voucher must be presented along with a valid prescription at the time of purchase. This offer may be changed or discontinued at any time without notice by Veloxis. Offer expires 12/31/2017. For questions, please call 1-844-728-3479. This is not a discount or rebate, and is not conditioned upon any past, present, or future purchase.
GENERAL INFORMATION

REGISTRATION DESK
Thursday 11:00 AM – 7:00 PM
Friday 7:00 AM – 4:00 PM
Saturday 7:00 AM – 4:00 PM

EXHIBIT HALL (POSTERS AND INDUSTRY DISPLAYS)
Thursday 4:00 PM – 7:00 PM
Friday 10:00 AM – 4:00 PM
Saturday 10:00 AM – 4:00 PM

INDUSTRY DISPLAYS
Be sure to visit the following companies in the exhibit hall during breaks and reception:
  - Astellas Pharma
  - CareDx
  - Novartis Pharmaceuticals Corporation
  - Sanofi Genzyme
  - Veloxis Pharmaceuticals
  - VitaerisBio

EVENING EVENTS
Welcome Reception and Posters
Thursday 5:45 PM – 7:00 PM
Join your colleagues for a warm welcome to the Cutting Edge of Transplantation (CEoT) meeting. View the posters, visit the exhibit booths, and enjoy ample food and drinks with AST.

Poolside Reception, Paradise Pool
Saturday 5:00 PM – 7:00 PM
Conclude your CEoT experience by winding down Poolside with your colleagues.

MEALS
Breakfast and lunch will be provided by AST Friday and Saturday in the FLW Ballroom. Break refreshments will be provided and served in the Exhibit Hall. Please refer to program agenda for time details. Please visit the hotel concierge or the AST registration desk for dining suggestions.

NAME BADGE
All attendees must wear the AST-provided name badge always to gain access to CEoT events and sessions.

GUESTS
All guests must be registered and wear their name badge to access the evening reception on Thursday. All other sessions and events are educational in nature and we request that guests do not attend.

WIFI
Network Name: AZB Meetings
Password: ast2018
PROGRAM PLANNING COMMITTEE

Anil Chandraker, MD, FASN, FAST, FRCP
Co-Chair and Board Liaison
Brigham & Women’s Hospital

Kenneth A. Newell, MD, PhD, FAST
Co-Chair
Emory University School of Medicine

Andrew B. Adams, MD, PhD
Emory University School of Medicine

Charles Alexander, RN, MSN, MBA, CPTC
The Living Legacy Foundation of Maryland

Roy Bloom, MD
Hospital of the University of Pennsylvania

David P. Foley, MD, FACS
University of Wisconsin

Richard N. Formica, Jr., MD
Yale University School of Medicine

Robert S. Gaston, MD
University of Alabama at Birmingham

John Gill, MD, MS
Providence Health Vancouver, BC

David Goldberg, MD, MSCE
Hospital of the University of Pennsylvania

Jon Kobashigawa, MD
Cedars Sinai Heart Institute

Jesse Schold, PhD, M. Stat, M.Ed.
Cleveland Clinic Foundation

Alexander Wiseman, MD
University of Colorado of Denver HSC
INVITED FACULTY AND MODERATORS

Andrew Adams, MD, PhD
Emory University School of Medicine

Jonathan D’Cunha, MD
University of Pittsburgh Medical Center

John Gill, MD, MS
Providence Health

Charles Alexander, RN, MSN, MBA, CPTC
The Living Legacy Foundation of Maryland

Gundeept Dhillion, MD, MS
Stanford University

Alexandra Glazier, JD, MPH
New England Donor Services

James Allan, MD, MBA, FAST
Massachusetts General Hospital

Thomas Egan, MD, MSc
UNC Chapel Hill

David Goldberg, MD, MSCE
University of Pennsylvania

Francisco Arabia, MD
Cedars Sinai Heart Institute

Jean Emond, MD
Columbia University

Melissa Greenwald, MD
Health Resources and Services Administration

Abbas Ardehali, MD
UCLA Medical Center

William Federspiel, PhD
McGowan Institute for Regenerative Medicine, UPMC

Shelley Hall, MD
Baylor University Medical Center

Agnes Azimzadeh, PhD
University of Maryland School of Medicine

David Foley, MD, FACS
University of Wisconsin School of Medicine and Public Health

Congresswoman Jaime Herrera Beutler, (R-WA)

Sangeeta Bhorade, MD
Northwestern Memorial Hospital

Richard Formica, MD
Yale University School of Medicine

Charles Hoopes, MD
University of Alabama

Roy Bloom, MD
Hospital of the University of Pennsylvania

O.H. Frazier, MD
Texas Heart Institute

Val Jeevanandum, MD
University of Chicago

Nicholas Braus, MD
Mayo Clinic

Richard Formica, MD
Yale University School of Medicine

Stephen Joel Coons, PhD
Critical Path Institute

Anil Chandraker, MD, FASN, FAST, FRCP
Brigham & Women’s Hospital

Bertram Kasiske, MD
Hennepin County Medical Center

Matthew Cooper, MD
Georgetown University

Shaf Keshavjee, MD
University of Toronto

Duane Davis, MD
Florida General Hospital

Robert Gaston, MD
University of Alabama at Birmingham

Allan Kirk, MD, PhD
Duke University Medical Center

David Klassen, MD
United Network for Organ Sharing
INVITED FACULTY AND MODERATORS (CONTINUED)

Liviu Klein, MD  
University of California, San Francisco

Axel Rahmel, PhD  
Deutsche Stiftung Organtransplantation

Joseph Tector, MD, PhD  
The Kirklin Clinic of UAB Hospital

Jon Kobashigawa, MD  
Cedars Sinai Heart Insitute

Jesse Schold, PhD, M. Stat, M. Ed  
Cleveland Clinic Foundation

Jeffrey Teuteberg, MD  
Stanford University School of Medicine

Joren Madsen, MD  
Massachusetts General Hospital

Palak Shah, MD  
Inova Heart & Vascular Institute

Nicole Turgeon, MD  
Emory University

Darren Malinoski, MD  
VA Portland Healthcare System

Farooq Sheikh  
MedStar Health

Christopher Wigfield, MD  
Advocate Christ Hospital

Simon Maltais, MD  
Massachusetts General Hospital

Brian Shepard, MBA  
United Network for Organ Sharing

Martin Zamora, MD  
University of Colorado Health Sciences Center

Roslyn Mannon, MD  
University of Alabama

Jason Smith, MD  
University of Washington

Arthur Matas, MD  
University of Minnesota

Michael Smith, MD  
St. Joseph’s Hospital

Ulf Meier-Kriesche, MD  
Veloxis Pharmaceuticals

Rachel Smith, PhD  
Cedars Sinai Heart Institute

Farooq Sheikh  
MedStar Health

Jonathan Swan, PhD  
Scientific Registry of Transplant Recipients

Congressman Eric Swalwell, (D-CA)

David Neujhar, MD  
Emory University

Mark Stegall, MD  
Mayo Clinic

Kenneth Newell, MD, PhD, FAST  
Emory University School of Medicine

Darren Stewart, MS  
United Network for Organ Sharing

Kevin O’Conner MS, PA  
LifeCenter Northwest

Congressman Eric Swalwell, (D-CA)

Robin Pierson, MD  
University of Maryland

Congressman Eric Swalwell, (D-CA)

Luke Preczewski  
Jackson Health System

Congressman Eric Swalwell, (D-CA)

Doris Taylor, MD  
Texas Heart Institute
The Latest Innovation in Kidney Transplant Surveillance

CareDx, Inc. invites you to a lunch symposium* to learn about:

Innovation in Allograft Health Surveillance: Clinical Implementation of Cell-Free DNA Testing for Transplant Patients

Friday, February 9, 2018 in Frank Lloyd Wright Salon EF at 12:15 pm

Moving molecular diagnostics from bench to bedside: Clinical implementation in kidney transplant patients

Peter S. Heeger, M.D., Professor of Medicine, Director of Transplant Research, Icahn School of Medicine at Mount Sinai

Early clinical experience with AlloSure in kidney transplant patients

Matthew Weir, M.D., Professor of Medicine, Director of the Division of Nephrology, University of Maryland School of Medicine

Implementation of AlloSure into clinical practice

Alexander Wiseman, M.D., Professor of Medicine, Medical Director, Renal and Transplant Programs, University of Colorado

Clinical application of donor-derived cfDNA testing for heart transplant surveillance

Jon A. Kobashigawa, M.D., Thomas D. Gordon, Professor of Medicine, and Director of the Heart Transplant Program, Cedars-Sinai Medical Center

*This is not an official function of the CeOT Meeting and is not endorsed by AST

Contact Us: 1-888-255-6627 | customercare@caredx.com
The Molecular Microscope®,
Launching the Next Generation of Transplant Diagnostics

07:00-08:15  Frank Llyod Wright Salon EF

PRESENTERS

Philip F. Halloran MD, Ph.D
Alberta Transplant Applied Genomics Centre

The New MMDx Reports; What They Say, What They Mean And How To Use Them

Gaurav Gupta, MD
Virginia Commonwealth University

Applying Molecular Diagnostics In Analyzing Renal Allograft Biopsies, The Richmond Experience

Alexandre Loupy, MD, Ph.D
Necker Hospital

Refining Integrative Diagnostic Standards In Transplantation, The Paris Experience

(This is not an official function of the CEOT Meeting and is not endorsed by AST.) Breakfast provided by AST.
### THURSDAY, FEBRUARY 8, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
</table>
| 1:45 PM | Welcome Remarks                                                         | Frank Lloyd Wright Salon EF  
Anil Chandraker, MD, FASN, FAST, FRCP  
Kenneth Newell, MD, PhD, FAST, Emory University |
| 2:00 PM | Session 1: Xenotransplantation, Are We Finally Ready? A Field, Challenging and Challenged by Regulation* | Andrew Adams, MD, PhD  
James Allan, MD, MBA, FAST |
| 2:05 PM | We Are Ready for Prime-Time, Invest Today!                              | Joseph Tector, MD, PhD                                                     |
| 2:30 PM | We’re Close but We Need to Consider the Following Issues Before Sinking in Your Money | Andrew Adams, MD, PhD                                                     |
| 2:55 PM | Hold on Here, Your Money Might be Better Invested Somewhere Else         | Allan Kirk, MD, PhD                                                       |
| 3:45 PM | Break                                                                   |                                                                           |
| 4:00 PM | Session 2: Defining True Innovation - Lessons from Transplantation’s Past* | Kenneth Newell, MD, PhD  
Anil Chandraker, MD, FASN, FAST, FRCP |
| 4:05 PM | Innovation in Surgical Technique – Living Donor Liver Transplantation   | Jean Emond, MD                                                            |
| 4:20 PM | Innovation in Immunosuppression                                         | Arthur Matas, MD                                                           |
| 4:35 PM | Innovation in Organ Donation                                            | Darren Malinoski, MD                                                      |
| 4:50 PM | Innovation in Regulatory Framework – the National Academy of Science Study | Alexandra Glazier, JD, MPH  
Panel Discussion |
| 5:45 PM | Poster & Welcome Reception                                              | Frank Lloyd Wright Salon G                                                |

*Continuing education credit offered. See separate packet.

### FRIDAY, FEBRUARY 9, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM</td>
<td>Continental Breakfast</td>
<td></td>
</tr>
</tbody>
</table>
| 9:00 AM | Congressional Keynote Speaker                                           | The Honorable Congressman Eric Swalwell (D-CA)  
U.S. House of Representatives |
| 9:45 AM | Break                                                                   |                                                                           |
| 10:00 AM| Session 3: Select One of Three Sessions                                  |                                                                           |
| 10:00 AM| OPTN/UNOS Policies and Organ Utilization - Necessary and Beneficial, or Obstacles to Growth & Innovation?* | Frank Lloyd Wright EF  
Moderators: Richard Formica, MD |
| 10:00 AM| Deceased Donors Starting Living Donor Chains                            |                                                                           |
| 10:00 AM| The Rationale and Potential Benefit for Using Deceased Donors to Start KPD Chains | Nicole Turgeon, MD                                                        |
| 10:10 AM| The Legal and Regulatory Issues Posed by Using Live Donors to Start KPD Chains | David Klassen, MD                                                        |
| 10:20 AM| Panel Discussion                                                         |                                                                           |
| 10:30 AM| New Paradigms for Allocating Organs - When Should Utility Override Equity? |                                                                           |
| 10:30 AM| European Perspective on Expedited Allocation                            | Axel Rahmel, PhD                                                          |
| 10:40 AM| Novel Ideas for Expedited Allocation                                    | Darren Stewart, MS                                                         |
| 10:50 AM| Proposing a New Paradigm -Less Choice, More Allocation                  | Jesse Schold, PhD, M. Stat, M.Ed                                          |
| 11:00 AM| Panel Discussion                                                         |                                                                           |

*Continuing education credit offered. See separate packet.
†No continuing education credit offered.
Re-Envisioning OPTN/UNOS

11:20 AM  People and Data
Brian Shepard, MBA

Richard Formica, MD

11:40 AM  HRSA Role as a Force Innovation in Transplantation
Melissa Greenwald, MD

11:50 AM  UNOS Labs: Leveraging Behavioral Science to Improve Organ Allocation
Darren Stewart, MS

OPTION TWO

Heart Track: Rise of the Machines - Regulatory Considerations in MCS Therapy*
Frank Lloyd Wright Salon AB
Moderators: Liviu Klein, MD
Rhondalyn Ford-McLean, MD

10:00 AM  LVADs as Destination Therapy - When Best Practice Criteria Meets the Real World
Faroq Sheikh, MD

10:15 AM  The Total Artificial Heart – What Metrics Should be Met for Standard Use? For Future Technology?
Francisco Arabia, MD

10:30 AM  ECMO and Short Term Support - Utilization Guidelines and Impact of the New Heart Allocation System
Jeffrey Teuteberg, MD

10:45 AM  MCS Complications - Understanding Risks and Rewards in the Context of Appropriate Use Benchmarks
Liviu Klein, MD

11:00 AM  DEBATE: Innovation in MCS Technology is Helped by Regulation
Palak Shah, MD

Innovation in MCS Technology is Hindered by Regulation
O.H. Frazier, MD

11:30 AM  The Cost of Success vs the Cost of Failure - Financial Considerations in Advancing Innovation
Simon Maltais, MD

OPTION THREE

Lung Track: The Evolution of Lung Support Devices - Regulatory Considerations in Lung Transplantation*
Frank Lloyd Wright Salon CD
Moderators: Sangeeta Bhorade, MD
Christopher Wigfield, MD

10:00 AM  ECMO as a Bridge to Transplant Should be Exempt from 1 Year Mortality Outcomes in Lung Transplant
– Con
Charles Hoopes, MD

– Pro
Duane Davis, MD

10:40 AM  Ex Vivo Lung Perfusion is an Essential Tool for Donor Optimization

11:20 AM  The Regulatory Imperative - Impact on the Practice of Lung Transplant
Christopher Wigfield, MD

11:35 AM  Regulatory Realities - Redefining Benefit of Lung Transplant in the Current Era
Gundeep Dhillon, MD, MS

– Pro
Shaf Keshavjee, MD

– Con
Thomas Egan, MD, MSc

12:15 – 1:30 PM  Satellite Symposium presented by CareDx, Inc †
This is not an official function of the CEoT meeting and is not endorsed by the AST.

1:30 – 2:15 PM  Congressional Keynote Speaker
The Honorable Congresswoman Jaime Herrera Beutler (R-WA)
U.S. House of Representatives

2:15 PM  Inaugural AST Innovation Award Presentation
Anil Chandraker, MD, FASN, FAST, FRCP
This new award was created to showcase a project or program that exemplifies the spirit of innovation on which transplantation was founded. Join us to honor the recipient, and hear a brief presentation on the program’s successful, outside-the-box approach that earned it the first Innovation Award.

*Continuing education credit offered. See separate packet.
†No continuing education credit offered.
OPTION ONE

Session 5:
Select One of Three Sessions

Program-Specific Reports: Past, Present and Future. Where do we go from here?*
Frank Lloyd Wright EF
Moderators: Jesse Schold, PhD, M. Stat, M. Ed
John Gill, MD, MS

2:50 PM
The Past
Bertram Kasiske, MD

3:05 PM
The Present
Jon Snyder, PhD

3:25 PM
The Future – What Would an Ideal Report Card Look Like?
Melissa Greenwald, MD
Jon Friedman, MD, FAST
Luke Preczewski
Jesse Schold, PhD, M.Stat, M. Ed

Panel Discussion

OPTION TWO

Heart Track: Alternatives to Heart Transplantation - Overcoming Barriers to Success*
Frank Lloyd Wright AB
Moderators: Joren Madsen, MD
Shelley Hall, MD

2:45 PM
DCD Heart Donation – Understanding the Regulatory and Ethical Issues
Val Jeevanandum, MD

3:05 PM
Xenotransplantation – Promise and Pragmatism
Robin Pierson, MD

3:25 PM
Whole Organ Engineering – Science and Sensibility
Doris Taylor, MD

3:45 PM
Stem Cell Therapy – Engineering Process
Rachel Smith, PhD

4:15 PM
Ex Vivo Heart Perfusion – Removing Time and Distance Barriers
Abbas Ardehali, MD

OPTION THREE

Lung Track: Trials, Tribulations and Triumphs in Lung Transplant Innovations
Frank Lloyd Wright CD
Moderators: Martin Zamora, MD
Duane Davis, MD

2:45 PM
Cell Free DNA and Other Immune Monitoring Techniques in Lung Transplantation – Are We There Yet?
David Neujoh, MD

3:05 PM
Controlled Donation After Determination of Circulatory Death (cDCDD) – Improving Yield
Michael Smith, MD

3:25 PM
Xeno Lung Transplantation – The Path Forward
Agnes Azimzadeh, PhD

3:45 PM
Extracorporeal Lung Support – A Bridge Too Far?
Jonathan D’Cunha, MD

4:15 PM
The Artificial Lung – Can it be Realized?
Williams Federspiel, PhD

SATURDAY, FEBRUARY 10, 2018

7:00 – 8:15 AM
Satellite Symposium presented by One Lambda Inc., A Thermo Fischer Scientific Brand
† This is not an official function of the CEoT meeting and is not endorsed by the AST.

8:15 AM
Break

8:30 – 10:00 AM
Session 6:
Select One of Two Sessions

OPTION ONE

Clinical Therapeutics to Improve Patient Outcomes - The Tribulations of Trials in Transplantation*
Frank Lloyd Wright EF
Moderators: Roy Bloom, MD
Roslyn Mannon, MD

8:30 AM
Tracking Transplant Treatment Trials - Where Are We and What are the Barriers
Roy Bloom, MD

9:00 AM
Victims of Success- Do We Still Need Clinical Trials and If So, What are Our Needs?
Robert Gaston, MD

9:30 AM
Can We Get There? Re-Thinking Clinical Trial Design
Jesse Schold, PhD, M.Stat, M.Ed.

9:45 AM
Panel Discussion with
Renata Albrecht, MD
Peter Maag, PhD
Kevin Campbell

*Continuing education credit offered. See separate packet.
†No continuing education credit offered.
OPTION TWO

**Case Studies in Thoracic Transplantation - Integrating Innovation***
Frank Lloyd Wright AB
Moderators: Jon Kobashigawa, MD
Nicholas Braus, MD

8:30 AM
Extended Criteria Heart vs Destination LVID
Liviu Klein, MD

8:45 AM
Hep-C Heart and Lung Transplantation
Shelley Hall, MD
Luke Cunningham, MD

9:00 AM
Ex Vivo Lung
Jon D’Cunha, MD
Lara Schaheen, MD

9:15 AM
Ex Vivo Heart
Jason Smith, MD
Christopher Burke, MD

9:30 AM
DCD Lung
Martin Zamora, MD
Nicholas Braus, MD

10:00 AM
Break

10:30 – 12:00 PM **Session 7: Approaches to Facilitating the Approval of New Therapeutics in Transplantation***
Frank Lloyd Wright EF
Moderators: Kenneth Newell, MD, PhD, FAST
Anil Chandraker, MD, FASN, FAST, FRCP

10:30 AM
Low and Not So Low Hanging Fruit – New Study Endpoints and Biomarkers
Ulf Meier-Kriesche, MD

10:50 AM
Regulatory Approaches to Facilitating the Use of Therapies Approved for Other Indications in Transplantation
Mark Stegall, MD

11:10 AM
PROs – New Opportunities to Measure Something That Matters to Patients
Stephen Joel Coons, PhD
Panel Discussion

12:15 PM – 1:30 PM
**Session 8: Out of Synch - How Can Factors That Drive OPO and Transplant Center Practice be Aligned to Increase the Number of Patients Who Receive a Transplant??*
Frank Lloyd Wright EF
Moderators: John Gill, MD, MS
David Foley, MD, FACS

1:30 PM
Critique of the Current OPO Performance Metrics and Proposed Improvements:
Characteristics of an Optimal OPO Metric
David Goldberg, MD, MSCE
My Pick for A New OPO Metric
Charles Alexander, RN, MSN, MBA, CPTC

1:45 PM
Regulatory and Financial Considerations That Impact OPO Performance – What Changes Would Increase Transplantation?
Kevin O’Connor, MS, PA

2:00 PM
Regulatory and Financial Considerations That Impact Transplant Center Practice – What Changes Would Increase Transplantation?
Matthew Cooper, MD

2:15 PM
Reaction to the Proposed Solutions
Brian Shepard, MBA

2:30 PM
Panel Discussion with
Jon Snyder, PhD

3:00 – 3:30 PM **Session 9: Summary Heart/Lung Track**
Frank Lloyd Wright AB
Jon Kobashigawa, MD
Sangeeta Bhorade, MD

3:30 – 4:00PM **Session 10: Summary and Next Steps**
Frank Lloyd Wright EF
Anil Chandraker, MD, FASN, FAST, FRCP
Kenneth Newell, MD, PhD, FAST

4:00 – 4:15 PM
Closing
Frank Lloyd Wright EF
Anil Chandraker, MD, FASN, FAST, FRCP
Kenneth Newell, MD, PhD, FAST

5:00 PM
Poolside Reception
Paradise Pool

*Continuing education credit offered. See separate packet.
†No continuing education credit offered.
The American Society of Transplantation sincerely thanks the following companies and organizations for their generous support of AST and its activities:

**AST 2017 SUPPORTERS**

**GOLD**

- astellas

**PATRON**

- C.S.
- MERCK
- Walgreens

**SILVER**

- Novartis
- Russell A. Lagasse Trust
- Sanofi Genzyme

**FRIEND**

- ASHI
- Canadian Blood Services
- CareDx
- Encompass Health
- Gilead
- Immucor
- National Institutes of Health
- Vanguard Charitable
- Wood MacMillan Charitable Fund

**BRONZE**

- Bristol-Myers Squibb
- Genentech
- One Lambda
- Shire
- Veloxis Pharmaceuticals

**AST 2018 CORPORATE AFFILIATES**

- CareDx
- MERCK
- Novartis
- One Lambda
- Sanofi Genzyme
- Shire
- Veloxis Pharmaceuticals

*at time of printing*
You have the power to save lives.
Get involved today with AST’s Power2Save initiative and show your support to make organ transplantation not just a treatment, but a cure!

Here are all the ways you can help:

SHARE:
We want to hear your story! Go online and record a video to share how you are connected to transplant and why others should get involved. With your help, we can inspire others!

FUNDRAISE:
Interested in supporting transplant research at a local level? Start a peer-to-peer fundraiser in lieu of birthday gifts or in honor of a loved one. It’s easy! Just visit www.power2save.org/get-involved to set up your personal fundraising page, and then invite your friends and family to view it. Any money donated will help transplant recipients live their dream of a full life.

FOLLOW:
Join others in raising awareness on Facebook and Twitter or register to get updates on our progress. We need your help to spread the word about the importance of transplantation research. You have the Power2Save! For more information, visit www.power2save.org/get-involved
AST CEot SUPPORTERS

At the time of printing

THIS EDUCATIONAL ACTIVITY IS MADE POSSIBLE WITH EDUCATIONAL GRANTS & SUPPORT FROM THE FOLLOWING COMPANIES:

- astellas
- CareDx
- Cedars-Sinai Heart Institute
- Hansa Medical
- NOVARTIS
- One Lambda
- Sanofi Genzyme
- Shire
- Veloxis Pharmaceuticals
SUPPORTERS AND EXHIBITORS INFORMATION

ASTELLAS PHARMA US, INC.
Astellas Pharma US, Inc., located in Northbrook, Illinois, is a US affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. For more information about Astellas Pharma US, Inc., please visit our website at www.Astellas.us.

HANSA MEDICAL
Hansa Medical is a biopharmaceutical company based in Sweden, developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead product is currently in late-stage clinical development for kidney transplant patients, with significant potential for further development in other solid organ transplants and in acute autoimmune indications. The company also has a strong pipeline of preclinical projects that may provide a second wave of potential drugs.

CAREDx
Caredx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnosis. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, Caredx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions.

CEDARS-SINAI HEART INSTITUTE
The Cedars-Sinai Heart Institute is home to a distinguished team of experts who are setting the bar for cardiac care in the United States. The Heart Institute unites 16 centers and programs to diagnose and treat the full spectrum of heart conditions for all patients, from infants to those with advanced disease.

Compassionate care is integrated with an agile research enterprise, giving patients access to pioneering treatments. Led by Eduardo Marbán, MD, PhD, our faculty and attending physicians provide deep expertise across all specialties, including transplantation, stem cell therapy, congenital heart disease, women’s heart health, valve disorders, arrhythmia and hypertension.

NOVARTIS PHARMACEUTICALS CORPORATION
Novartis Pharmaceuticals Corporation has been committed to the field of transplantation for more than 30 years. With the broadest portfolio of transplant medicines in the industry, we remain dedicated to the transplant community through our research and innovation. From the exploration of new pathways and molecules to continued clinical trial investment, patients are at the center of all we do. We are proud to collaborate with leading professional and advocacy organizations in the transplant community to raise awareness of critical unmet needs in transplantation. Through a number of novel educational and awareness-raising initiatives, we are focused on expanding patients’ access to life-saving organ transplants.

SHIRE
Newly combined with Baxalta, Shire is now the leading global biotechnology company focused on serving people affected by rare diseases and highly specialized conditions. These diseases are often misunderstood, under-diagnosed, and potentially life-threatening. Our 22,000 employees come to work every day with a common purpose: to develop and deliver breakthrough therapies that enable people with life-altering conditions to live their lives to the fullest.

At Shire, we are dedicated to expanding, building and sustaining leadership across our key therapeutic areas through our extensive portfolio of products, innovative pipeline and collaborative approach to working with diverse partners around the globe. We strive to earn and keep the trust of our patients, their families and physicians, and all others who support and advance their care.

VELOXIS PHARMACEUTICALS
Veloxis is a specialty pharmaceutical company committed to improving the lives of transplant patients. Our unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs.

VITAERISBIO
Founded in 2016, Vitaeris is a clinical-stage biopharmaceutical company based focused on the development of the anti-interleukin-6 (IL-6) monoclonal antibody clazakizumab for chronic Antibody Mediated Rejection (cAMR). Clazakizumab is a best-in-class IL-6 antagonist that has been studied in clinical trials involving over one thousand patients worldwide out side the transplant setting. A phase 3 clinical study for cAMR is proposed to start in 2018. More at vitaerisbio.com
OVER 30 YEARS OF WORKING TOGETHER TO HELP ADDRESS PATIENT NEEDS
COMMITTED TO ADVANCING TRANSPLANTATION FOR MORE THAN 20 YEARS
FELLOWS SYMPOSIUM ON TRANSPLANTATION 2018

SAVE THE DATE

SEPTEMBER 28-30, 2018
Hilton DFW Lakes Executive Conference Center • Grapevine, TX
myAST.org
YOUNG INNOVATOR AWARD WINNERS

OSWALDO AGUIRRE
Medstar Georgetown University Hospital
Washington, DC

KATHERINE ROSS
Emory University
Atlanta, GA

ALI AHMADI
The Johns Hopkins University School of Medicine
Baltimore, MD

VASISHTA TATAPUDI
New York University Medical Center
New York, NY

MADONNA RICA ANGGELIA
Chang Gung Memorial Hospital
Linkou, Taiwan

ARPITA BASU
Mayo Clinic
Rochester, MN

NATALIE BATH
University of Wisconsin
Madison, WI

JOSEPH LADOWSKI
University of Alabama-Birmingham
Birmingham, AL

TAYLOR MELANSON
Emory University
Atlanta, GA
POSTER ABSTRACTS
<table>
<thead>
<tr>
<th>ABSTRACT#</th>
<th>YIA1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depletion Resistant Memory T Cells Mediate Thymoglobulin Refractory Intestinal Allograft Rejection</td>
<td></td>
</tr>
<tr>
<td>Authors: Brenna Houlihan, MD¹, Abdullah Karabala, MD¹, Raffaele Girlanda, MD¹, Jason Hawksworth, MD¹, Cal Matsumoto, MD¹, Michael Zasloff, MD, PhD¹, Alexander Kroemer, MD, PhD¹, Thomas Fishbein, MD¹, Oswaldo Aguirre, MD¹</td>
<td></td>
</tr>
<tr>
<td>Institutions (ALL): 1. Medstar Georgetown University Hospital</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT#</th>
<th>YIA2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment with AMD3100 and Low Dose FK506 Mitigates IRI Induced Severe Acute Kidney Injury</td>
<td></td>
</tr>
<tr>
<td>Authors: Wei Wang, Le Qi, Jinny Huang, BS, Aravind Krishnan, James Burdick, Andrew Cameron, MD, George Williams, Zhaoli Sun, Ali Ahmadi, BSc¹</td>
<td></td>
</tr>
<tr>
<td>Institutions (ALL): 1. The Johns Hopkins University School of Medicine</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT#</th>
<th>YIA3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Role of Tregs in Tolerance Induction in Mouse Vascularized Osteomyocutaneous Allotransplantation</td>
<td></td>
</tr>
<tr>
<td>Authors: Huang-Yu Yang¹, Hui-Yun Cheng¹, Wen-Yu Chang¹, Fu-Chen Wei¹, Gerald Brandacher³, Cheng-Hung Lin¹, Madonna Rica Anggelia, PhD Candidate³</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT#</th>
<th>YIA4</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Advantage of Utilizing ABO and HLA Compatible Pairs in Kidney Paired Donation</td>
<td></td>
</tr>
<tr>
<td>Authors: Carrie Schinstock, MD¹, Hasan Khamash, MD², Catherine Kosberg, RN, CCTC¹, Martin Mai, MD³, Mikel Prieto, MD¹, Arpita Basu, MD, MPH⁴</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT#</th>
<th>YIA5</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLyS Deficient Rats Prevent Donor Specific Antibody Production and Proliferation in Rodent Model</td>
<td></td>
</tr>
<tr>
<td>Authors: Bret Verhoven, BS¹, Nancy Wilson, PhD¹, Shannon Reese, MS¹, Sarah Panzer, MD¹, Robert Redfield, MD¹, Natalie Bath, MD¹</td>
<td></td>
</tr>
<tr>
<td>Institutions (ALL): 1. University of Wisconsin</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT#</th>
<th>YIA6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genetically Engineering Kidneys for the Highly Sensitized</td>
<td></td>
</tr>
<tr>
<td>Authors: Gregory Martens, MD¹, Luz Reyes, MSc, PhD¹, Zheng-Yu Wang, MD, PhD¹, Matthew Tector¹, Alfred Tector, MD, PhD, FACS¹, Joseph Ladowski, MS¹</td>
<td></td>
</tr>
<tr>
<td>Institutions (ALL): 1. University of Alabama-Birmingham</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT#</th>
<th>YIA7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Variation in Living Donor Kidney Transplantation Among U.S. Transplant Centers</td>
<td></td>
</tr>
<tr>
<td>Authors: Katie Ross, MPF, Laura Plantinga, Sumit Mohan, Stephen Pastan, MD, Mohua Basu, MPF, Rachel Patzer, PhD, Taylor Melanson, BA¹</td>
<td></td>
</tr>
<tr>
<td>Institutions (ALL): 1. Emory University</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT#</th>
<th>YIA8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Racial Disparities in Post-Liver Transplant Survival Before and After Share 35 Implementation</td>
<td></td>
</tr>
<tr>
<td>Authors: Raymond Lynch, MD¹, Rachel Patzer, PhD¹, Katherine Ross, MPH²</td>
<td></td>
</tr>
<tr>
<td>Institutions (ALL): 1. Emory Transplant Center 2. Emory University</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT#</th>
<th>YIA9</th>
</tr>
</thead>
<tbody>
<tr>
<td>A2/A2B to B Renal Transplantation: Outcomes Since Implementation of New Kidney Allocation System</td>
<td></td>
</tr>
<tr>
<td>Authors: Elijah Min, Nicole Ali, MD, Bruce Gelb, MD, Nabil Dagher, MD, Judith Benstein, Bonnie Lonze, MD PHD, Vasishta Tatapudi, MD¹</td>
<td></td>
</tr>
<tr>
<td>Institutions (ALL): 1. New York University Medical Center</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT#</th>
<th>A10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frailty Assessment Pilot Study In Older Kidney Transplant Recipients</td>
<td></td>
</tr>
<tr>
<td>Authors: Bethany Hale-Durbin, RN, BSN, CPTC, CCTC¹, Christine Lee, RN¹, Joanna Schaenman, MD, PhD¹, Gabriel Danovitch, MD¹, Basmah Abdalla, MD¹</td>
<td></td>
</tr>
<tr>
<td>Institutions (ALL): 1. University of California, Los Angeles</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ABSTRACT#</th>
<th>A11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-Admissions, Resource Utilization and Survival After Kidney-Pancreas Transplantation</td>
<td></td>
</tr>
<tr>
<td>Authors: Rebecca Zhang, MS¹, Ronald Parsons, MD², Andrew Adams, MD, PhD², Rachel Patzer, PhD¹, Raymond Lynch, MD², Douglas Anderson, MD¹</td>
<td></td>
</tr>
<tr>
<td>Institutions (ALL): 1. Emory University 2. Surgery</td>
<td></td>
</tr>
</tbody>
</table>
ABSTRACT# A12
Successful Treatment of HCV Infection with Direct Acting Antivirals after Renal Transplantation
Authors: Atsushi Nakamura, MD, Izumi Haga, Tetsuro Takayama, Noritoshi Amada, Naoki Kawagishi, MD
Institutions (ALL): 1. JCHO Sendai Hospital

ABSTRACT# A13
Retrospective Analysis Of Occult Cardiac Disease In Kidney Transplant Candidates
Authors: Sharon Klarman, RN
Institutions (ALL): Yale

ABSTRACT# A14
CMV Seromatching and Effect on Waiting Times
Authors: Jesse Schold, PhD, M Stat, MEd, Ali Olyaei, Brent Gardner, Douglas Norman, MD, Joe Lockridge, MD
Institutions (ALL): 1. Cleveland Clinic
2. Oregon Health and Sciences University

ABSTRACT# A15
Morphometric and Metabolic Correlates of Frailty in Pancreas Transplant Recipients
Authors: Jakub Woloszyn, Ronald Parsons, MD, Raymond Lynch, MD
Institutions (ALL): 1. Emory Transplant Center

ABSTRACT# A16
Renal Transplant Recipients with History of Malignant Melanoma, and Post-Transplant Outcomes.
Authors: Erik Lum, Shaker Qaqish, MBBS
Institutions (ALL): 1. University of California, Los Angeles

ABSTRACT# A17
Increased Successful Transplants in Sensitized Patients Using a New IgG Subtype Assay
Authors: Dayanand Deo, PhD, Prakash Rao, PhD, MBA, FACHE, HCLD
Institutions (ALL): 1. New Jersey Sharing Network

ABSTRACT# A18
Histogenomics: Molecular Profiling of Kidney Biopsies Predict Delayed Graft Function
Authors: Dayanand Deo, PhD, Prakash Rao, PhD, MBA, FACHE, HCLD
Institutions (ALL): 1. New Jersey Sharing Network

ABSTRACT# A19
Impact of Antiviral Therapy for HCV on Rejection and DSA Formation in Kidney Transplant Recipients.
Authors: Ziad Zaky, MD
Institutions (ALL): Cleveland Clinic

ABSTRACT# A20
Associated Risk for Weight Gain Post-Kidney Transplantation with A New Criteria for Hypertension
Authors: Ekamol Tantisattamo, MD, Praveen Ratanasrimetha, MD, Possawat Vutthikraivit, MD, Raghavesh Pullalarevu, MD
Institutions (ALL): 1. Department of Internal Medicine, William Beaumont Hospital, Oakland University William Beaumont School of Medicine
2. Texas Tech University Health Sciences Center
3. Phramongkutklao College of Medicine, Mahidol University

ABSTRACT# B21
Assessing Response to Desensitization: What Makes Sense?
Authors: Evan Kransdorf, MD, PhD, Jignesh Patel, MD, PhD, Xiaohai Zhang, PhD, Marcelo Pando, PhD, Michelle Kittleson, MD, PhD, Lawrence Czer, MD, David Chang, MD, Sadia Dimbil, BS, Ryan Levine, BS, Kristine Norland, RN, Michele Hamilton, MD, Joshua Chung, MD, Jon Kobashigawa, MD, Jaime Moriguchi, MD
Institutions (ALL): 1. Cedars Sinai Heart Institute
2. Baylor Scott and White Health

ABSTRACT# B22
Pre-Transplant Memory Patients are at Rejection Risk in the First-Year after Heart Transplantation
Authors: Sadia Dimbil, BS, Jignesh Patel, MD, PhD, Evan Kransdorf, MD, PhD, Ryan Levine, BS, Lawrence Czer, MD, Jon Kobashigawa, MD, Jaime Moriguchi, MD
Institutions (ALL): 1. Cedars Sinai Heart Institute

ABSTRACT# B23
Donor-Derived Cell Free DNA May Detect Antibody-Mediated Rejection After Heart Transplantation
Authors: Michelle Kittleson, MD, PhD, Lawrence Czer, MD, David Chang, MD, Evan Kransdorf, MD, PhD, Sean Sana, MD, James Yee, MD, PhD, Robert Woodward, PhD, Ryan Levine, BS, Sadia Dimbil, BS, Daniel Luthringer, MD, Jon Kobashigawa, MD, Jignesh Patel, MD
Institutions (ALL): 1. Cedars Sinai Heart Institute
2. CareDx
ABSTRACT# B24
Long-Term Outcome of Photopheresis in Heart-Transplantation: Is It Worth It?
Authors: Evan Kransdorf, MD, PhD, Sadia Dimbil, BS, Ryan Levine, BS, Lawrence Czer, MD, Jaime Moriguchi, MD, Jon Kobashigawa, MD, Jignesh Patel, MD, PhD
Institutions (ALL): 1. Cedars Sinai Heart Institute

ABSTRACT# B29
Liver Biopsy Fibrosis Not Liver Imaging Predicts Survival After Heart Transplant
Authors: Evan Kransdorf, MD, PhD, David Chang, MD, Ken Nguyen, MD, Tran Tran, MD, Jignesh Patel, MD, PhD, Ryan Levine, BS, Sadia Dimbil, BS, Jaime Moriguchi, MD, Jon Kobashigawa, MD, Lawrence Czer, MD
Institutions (ALL): 1. Cedars Sinai Heart Institute 2. University of Texas Southwestern

ABSTRACT# B25
Waiting for the Optimal Donor for MCS Patients Awaiting Heart Transplant
Authors: Jaime Moriguchi, MD, Francisco Arabia, MD, Jignesh Patel, MD, PhD, Evan Kransdorf, MD, PhD, Sadia Dimbil, BS, Elizabeth Passano, MS, Lawrence Czer, MD, Jon Kobashigawa, MD, Ryan Levine, BS
Institutions (ALL): 1. Cedars Sinai Heart Institute

ABSTRACT# B30
Characterization of Vasoplegia Immediately After Heart Transplantation
Authors: Sadia Dimbil, BS, Jignesh Patel, MD, PhD, Evan Kransdorf, MD, PhD, Ryan Levine, BS, Joshua Chan, MD, Fardad Esmailian, Jaime Moriguchi, MD, Jon Kobashigawa, MD, Lawrence Czer, MD
Institutions (ALL): 1. Cedars Sinai Heart Institute

ABSTRACT# B26
Heart Transplant Across Low or Moderate Level Donor-Specific Antibodies Have Acceptable Outcome
Authors: Jignesh Patel, MD, PhD, Evan Kransdorf, MD, PhD, Sadia Dimbil, BS, Lawrence Czer, MD, Jaime Moriguchi, MD, Jon Kobashigawa, MD, Ryan Levine, BS
Institutions (ALL): 1. Cedars Sinai Heart Institute

ABSTRACT# B31
Outcome of Treated Sensitized MCS Patients After Heart Transplantation
Authors: Sadia Dimbil, BS, Jaime Moriguchi, MD, Jignesh Patel, MD, PhD, Evan Kransdorf, MD, PhD, Ryan Levine, BS, Elizabeth Passano, MS, Lawrence Czer, MD, Jon Kobashigawa, MD, Francisco Arabia, MD
Institutions (ALL): 1. Cedars Sinai Heart Institute

ABSTRACT# B27
Left Ventricular Assist Devices: Differences Based On Socioeconomic Status
Authors: Omar Sadiq, MD, Celeste Williams, MD, Lindsey Aurora, MD
Institutions (ALL): 1. Henry Ford Hospital

ABSTRACT# B32
A Novel Technique For Monitoring Extravascular Lung Water In Donor Lungs.
Authors: Toshihiro Okamoto, MD, PhD, Hiromichi Niikawa, MD, Yoshifumi Itoda, MD, PhD, Siddharth Dugar, MD, Samir Latifi, MD, Ajit Moghekar, MD, Kenneth McCurry, MD, Kamal Ayyat
Institutions (ALL): 1. Cleveland Clinic

ABSTRACT# B28
Gene Expression Profile Testing Scores Are Associated with New Onset Coronary Allograft Vasculopathy
Authors: Anu Lala, Sean Pinney, MD, Robert Woodward, PhD, David Hiller, PhD, Preethi Pirlamarla, MD
Institutions (ALL): 1. Mount Sinai Hospital

ABSTRACT# C33
Positive End-Expiratory Pressure Titration In Ex-Vivo Lung Perfusion
Authors: Toshihiro Okamoto, MD, PhD, Hiromichi Niikawa, MD, PhD, Yoshifumi Itoda, MD, PhD, Kenneth McCurry, MD, Kamal Ayyat
Institutions (ALL): 1. Cleveland Clinic
ABSTRACT# C34
Hyperinflation Can Predict Deterioration of Smoker’s Lung Function in Ex Vivo Lung Perfusion

Authors: Toshihiro Okamoto, MD, PhD,1, Hiromichi Niikawa, MD, PhD,1, Kamal Ayyat,1, Carol Farver, MD,1, Kenneth McCurry, MD,1, Yoshifumi Itoda, MD, PhD1

Institutions (ALL): 1. Cleveland Clinic

ABSTRACT# C35
The Importance of Duration of Ex Vivo Lung Perfusion for Marginal Donor Lungs

Authors: Toshihiro Okamoto, MD, PhD1, Hiromichi Niikawa, MD, PhD1

Institutions (ALL): 1. Cleveland Clinic

ABSTRACT# C36
Transplant Suitability of Rejected Human Donor Lungs in Two Ex Vivo Lung Perfusion Systems

Authors: Kenneth McCurry, MD,1, Toshihiro Okamoto, MD, PhD1

Institutions (ALL): 1. Cleveland Clinic

ABSTRACT# C37
Specialized Thoracic Adapted Recovery (STAR) Team Model for Heart and Lung Transplantation

Authors: Preben Brandenhoff, MD,1, Hassan Tetteh, MD2

Institutions (ALL): 1. University of Copenhagen
2. Uniformed Services University of Health Sciences

ABSTRACT# C38
AMD3100 As A Single-Dose Stem Cell Mobilizing Agent In VCA Transplantation In A Canine Model

Authors: Scott Graves, PhD,1, Rainer Storb, MD,1, David Mathes, MD,2, Bruce Swearingen, MD2

Institutions (ALL): 1. Fred Hutchinson Cancer Research Center
2. University of Colorado School of Medicine

ABSTRACT# D39
IgA Recurrence in a Single Center with a Protocol Biopsy Program

Authors: Hatem Amer, MD, Nicola Lepori, Fernando Cosio, Fernando Fervenza, Mireille El Ters, Massini Merzkani, MD1

Institutions (ALL): 1. Mayo Clinic

ABSTRACT# D40
Incorporating Geographic Catchment Areas in Kidney Transplant Center Measures of Transplant Rates

Authors: LaMont Sutton, MPH,1, Raymond Lynch, MD2, Rachel Patzer, PhD,2, Katherine Ross, MPH1

Institutions (ALL): 1. Emory University
2. Emory Transplant Center

ABSTRACT# D41
Novel Performance Metric to Improve Referral Rate for Kidney Transplants

Authors: Gideon Aweh, MS,1, Vlad Ladik,1, Pam Haverman,1, Robert Taylor, MD,1, Doug Johnson, MD,1, Eduardo Lacson, MD2

Institutions (ALL): 1. Dialysis Clinic, Inc.
2. Tufts University School of Medicine

ABSTRACT# D42
Innovation in Community-Based Transplant Mentorship Program: Overcoming Barriers to Living Donation

Authors: Anastasia Henry, BA

Institutions (ALL): American Transplant Foundation

ABSTRACT# D43
Cost Effectiveness of Lifelong Medicare Immunosuppressant Coverage for Kidney Transplant Recipients

Authors: John Gill, MD, MS,1, Jagbir Gill1, Scott Klarenbach2, Matthew Kadatz, MD1

Institutions (ALL): 1. University of British Columbia
2. University of Alberta

ABSTRACT# D44
Racial Differences in Medical Mistrust and Initiating Kidney Transplant Evaluation

Authors: Jennifer Gander, Reem Hamoda, Laura McPherson, Erica Hartmann, MD, Laura Mulloy, Carlos Zayas, MD, Stephen Pastan, MD, Rachel Patzer, PhD, Kristie Lipford, PhD1

Institutions (ALL): 1. Emory University

ABSTRACT# D45
The US Experience of Octogenarian Donor Kidney Transplantation from Analysis of UNOS/OPTN Registry

Authors: Zheng Zhu1, Silvi Shah1, Masaaki Yamada, MD1

Institutions (ALL): 1. University of Cincinnati
ABSTRACT# D46
Lines in the Sand: Navigating Existing Laws to Facilitate VCA and Organ Recovery
Authors: Helen Irving, RN MBA¹, Eduardo Rodriguez, MD DDS², Bruce Gelm, MD²
Institutions (ALL): 1. LiveOnNY
2. NYU Langone

ABSTRACT# D47
Impact Of PHS/OPTN High Risk Donors on The Waiting Time
Authors: Kelley Kulikowski, BSN, RN-BC¹, Ekamol Tantisattamo, MD¹, Danny Hollerud¹, Damjanpreet Bedi, MD¹, Steven Cohn¹, Alan Koifman¹, Dilip Samarapungavan¹, Raghavesh Pullalarevu, MD¹
Institutions (ALL): 1. William Beaumont Hospital, Royal Oak, MI

ABSTRACT# E48
Bortezomib Without Plasmapheresis Is Non-Inferior to Bortezomib With Plasmapheresis
Authors: Megan Kamath, MD
Institutions (ALL): University of California, Los Angeles

ABSTRACT# E49
The Role of Donor Selection on CMV Outcomes in Small Intestinal/ Multivisceral Transplant Recipients
Authors: Harkiran Grewal, MD¹, Cal Matsumoto, MD¹, Madhuri Natarajan, MPH¹, J. Hunter Fraker, BS, BA¹, Wei Fan, MD¹, Joseph Timpone, MD¹, Mary Czech, MD¹
Institutions (ALL): 1. MedStar Georgetown University Hospital

ABSTRACT# E50
Accepting Hepatitis C-Infected Organs – The Stanford Experience
Authors: Kiran Khush, MD, MAS¹, Aliya Gulamhusein, MD, MPH², Yasseraboo Moayedi, MD¹
Institutions (ALL): 1. Stanford University
2. University of Toronto

ABSTRACT# E51
Immunomonitoring Of Operational Tolerance In Intestinal Transplantation
Authors: Brenna Houlihan, MD¹, Raffaele Girlanda, MD¹, Jason Hawksworth, MD¹, Cal Matsumoto, MD¹, Michael Zasloff, MD, PhD¹, Thomas Fishbein, MD¹, Alexander Kroemer, MD, PhD¹, Oswaldo Aguirre, MD¹
Institutions (ALL): 1. Medstar Georgetown University Hospital

ABSTRACT# E52
CD8+ Tissue Resident Memory T Cells Are Key Effectors In Intestinal Transplant Patients With GvHD
Authors: Brenna Houlihan, MD¹, Abdulla Karabala, MD¹, Raffaele Girlanda, MD¹, Jason Hawksworth, MD¹, Cal Matsumoto, MD¹, Michael Zasloff, MD, PhD¹, Thomas Fishbein, MD¹, Alexander Kroemer, MD, PhD¹, Oswaldo Aguirre, MD¹
Institutions (ALL): 1. Medstar Georgetown University Hospital

ABSTRACT# E53
Organ-Specific Differences in a Belatacept-Based Protocol for Tolerance Induction in NHP
Authors: Wiebke Sommer, MD¹, Jane O, Kyu Ha Huh, Kortney Robinson, MD, Abbas Dehnadi, DVM, Isabel Hanekamp, Ivy Rosales, MD, Kurt Pruner, Josh Paster, Rex Smith, Robert Colvin, Tatsuo Kawai, MD PHD, Giles Benichou, PhD, Joren Madsen, MD, DPhil, James Allan
Institutions (ALL): 1. Massachusetts General Hospital
Please visit our booth at the AST’s CEoT 2018 meeting
HansaMedical.com
The Latest Innovation in Kidney Transplant Surveillance

AlloSure is the first and only, clinically and analytically validated, non-invasive test that assesses organ health by directly measuring allograft injury.

AlloSure is a blood test that measures donor-derived cell-free DNA and can accurately determine active rejection, enabling better management of your kidney transplant patients.

To learn more, please join us for a lunch symposium*
Innovation in Allograft Health Surveillance: Clinical Implementation of Cell-Free DNA Testing for Transplant Patients

Friday, February 9, 2018 in Frank Lloyd Wright Salon EF at 12:15 pm

*This is not an official function of the CEO Meeting and is not endorsed by AST

Contact Us: 1-888-255-6627 | customercare@caredx.com